Shopping Cart
- Remove All
Your shopping cart is currently empty
Bradykinin (acetate)
🥰Excellent
Catalog No. T21610Cas No. 6846-03-3
Bradykinin (acetate) is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions. Enzymatically produced from kallidin in the blood, it is a powerful vasodilator that causes smooth muscle contraction, and may mediate inflammation. It has a role as a human blood serum metabolite and a vasodilator agent. It is a tautomer of a bradykinin(2+).
Bradykinin (acetate)
🥰Excellent
Purity: 100%
Catalog No. T21610Cas No. 6846-03-3
Bradykinin (acetate) is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions. Enzymatically produced from kallidin in the blood, it is a powerful vasodilator that causes smooth muscle contraction, and may mediate inflammation. It has a role as a human blood serum metabolite and a vasodilator agent. It is a tautomer of a bradykinin(2+).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $37 | In Stock | |
| 5 mg | $56 | In Stock | |
| 10 mg | $84 | In Stock | |
| 25 mg | $148 | In Stock | |
| 50 mg | $243 | In Stock | |
| 100 mg | $429 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Bradykinin (acetate)"
Safotibant
LF22-0542, LF-22-0542, LF-220542, LF220542, LF 22-0542, LF 220542
T34485633698-99-4In house
Safotibant (LF-22-0542) is a bradykinin B1 receptor antagonist with anti-inflammatory and analgesic activity for the topical treatment of diabetic macular edema.
- $146
Size
QTY
ELN-441958
ELN 441958
T2086913064-47-8
ELN-441958 is a potent, neutral antagonist of the B1 receptor, inhibiting the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with a Ki of 0.26 nM. ELN-441958 (ELN 441958) is highly selective for B1 over B2 receptors.
- $56
Size
QTY
5-Hydroxy-1-methylhydantoin
NZ-419, NZ419, NZ 419, HD-003, HD003, HD 003
T2822284210-26-4
5-Hydroxy-1-methylhydantoin (HD-003) is an antioxidant potentially for the treatment of renal failure. A creatinine metabolite, 5-Hydroxy-1-methylhydantoin , a hydroxyl radical scavenger, has previously been shown to confer renoprotection by inhibiting the progression of chronic kidney disease in rats. 5-Hydroxy-1-methylhydantoin is a novel anti-oxidant drug completely suppressed the expression of B2-kinin receptors (B2KR) in response to high glucose (25 mM) stimulation in VSMC and was also shown to attenuate the effects of BK on VSMC remodeling. 5-Hydroxy-1-methylhydantoin inhibited the BK-induced increase in MAPK phosphorylation and attenuated the increase in connective tissue growth factor (CTGF) protein levels in VSMC. These findings suggest that 5-Hydroxy-1-methylhydantoin may confer vascular protection against high glucose concentrations and BK-stimulation to ameliorate vascular injury and remodeling through its anti-oxidant properties.
- $30
Size
QTY
Sar-[D-Phe8]-des-Arg9-Bradykinin acetate
Sar-[D-Phe8]-des-Arg9-Bradykinin acetate(126959-88-4 free base)
TP1917L1
Sar-[D-Phe8]-des-Arg9-Bradykinin acetate is a potent and selective bradykinin B1 receptor agonist (EC50 = 9.02 nM in rabbit aorta) that is resistant to aminopeptidase, kininase I and II (ACE) and neutral endopeptidase cleavage. Exhibits hypotensive and angiogenic activity in vivo.
- $185
Size
QTY
Lys-[Des-Arg9]Bradykinin acetate
Cited
Lys-[Des-Arg9]Bradykinin acetate (71800-36-7 free base)
TP1918L1
Lys-[Des-Arg9]Bradykinin acetate is an endogenous potent and highly selective bradykinin B1 receptor agonist (Ki values are 0.12 and > 30000 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. 16-fold more potent than [Des-Arg9]-Bradykinin.
- $81
Size
QTY
CitedMK-0686
MK0686
T33421578727-68-1In house
MK-0686 is an orally available bradykinin B1 receptor antagonist with potential anti-inflammatory activity.
- $191
Size
QTY
NPC 567 acetate
NPC 567 acetate(109333-26-8 Free base)
T21060L
NPC 567 acetate is a bradykinin B2 antagonist and can be used in studies about the treatment of allergic airway disease.
- $195
Size
QTY
Anatibant 2HCl
Anatibant 2HCl(209733-45-9 Free base)
T26627L209788-45-4In house
Anatibant 2HCl is a small molecule bradykinin B2 receptor antagonist for the treatment of neurological disorders and may be used in the study of brain injury.
- $350
Size
QTY
Lys-Bradykinin acetate(342-10-9 free base)
TP2268L84640-50-6
Lys-Bradykinin acetate is an endogenous bradykinin receptor agonist.
- $98
Size
QTY
(Hyp³)-Bradykinin acetate
(Hyp³)-Bradykinin acetate (37642-65-2 Free base)
T36442L
(Hyp³)-Bradykinin acetate is an agonist of bradykinin B2 receptor and stimulates inositol phosphate production in cultured human fibroblasts.
- $79
Size
QTY
[Des-Arg9]-Bradykinin acetate
TP144523827-91-0
[Des-Arg9]-Bradykinin acetate is a selective agonist of the Bradykinin B1 receptor.
- $47
Size
QTY
Select Batch
Purity:100%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Bradykinin (acetate) is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions. Enzymatically produced from kallidin in the blood, it is a powerful vasodilator that causes smooth muscle contraction, and may mediate inflammation. It has a role as a human blood serum metabolite and a vasodilator agent. It is a tautomer of a bradykinin(2+). |
| In vivo | Exogenous bradykinin markedly inhibited TF expression in mRNA and protein level induced by LPS in a dose-dependent manner.?Moreover, the NO synthase antagonist L-NAME and PI3K inhibitor LY294002 dramatically abolished the inhibitory effects of bradykinin on tissue factor expression.?PI3K/Akt signaling pathway activation induced by bradykinin administration reduced the activity of GSK-3β and MAPK, and reduced NF-x03BA;B level in the nucleus, thereby inhibiting TF expression.Intraperitoneal injection of C57/BL6 mice with bradykinin also inhibited the thrombus formation induced by ligation of inferior vena cava. |
| Animal Research | To study the effect of bradykinin on TF expression, we used Lipopolysaccharides (LPS) to induce TF expression in human umbilical vein endothelial cells and monocytes.?Transcript levels were determined by RT-PCR, protein abundance by Western blotting.?In the in vivo study, bradykinin and equal saline were intraperitoneally injected into mice for three days ahead of inferior cava vein ligation that we took to induce thrombus formation, after which bradykinin and saline were injected for another two days.?Eventually, the mice were sacrificed and tissues were harvested for tests[1]. |
| Molecular Weight | 1120.26 |
| Formula | C52H77N15O13 |
| Cas No. | 6846-03-3 |
| Smiles | CC(O)=O.N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
| Solubility Information | DMSO: 10 mM, Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Bradykinin (acetate) | purchase Bradykinin (acetate) | Bradykinin (acetate) cost | order Bradykinin (acetate) | Bradykinin (acetate) chemical structure | Bradykinin (acetate) in vivo | Bradykinin (acetate) formula | Bradykinin (acetate) molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.